Genmab receives orphan drug designation from FDA

The US Health authority has granted orphan drug status to Genmab’s lymphoma treatment, epcoritamab, which is being developed alongside Abbvie.

Photo: Tuala Hjarnø / Genmab / PR

Danish biotech company Genmab announces in a press release that the US Food and Drug Administration (FDA) has designated the company’s investigational drug, epcoritamab, an orphan drug.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs